Clinical trial
Open-label, Multicentre, Tolerability, Safety and Pharmacokinetics Study of the Medicinal Product BP-SCIG 20% (Human Normal Immunoglobulin for Subcutaneous Administration) Manufactured by BIOPHARMA PLASMA LLC, Followed by an Efficacy Assessment of Long-term Use in Patients With Primary Immunodeficiency (PID)
NCT07346859 is registered in ClinicalTrials.gov with Biopharma Plasma LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open-label, Multicentre, Tolerability, Safety and Pharmacokinetics Study of the Medicinal Product BP-SCIG 20% (Human Normal Immunoglobulin for Subcutaneous Administration) Manufactured by BIOPHARMA PLASMA LLC, Followed by an Efficacy Assessment of Long-term Use in Patients With Primary Immunodeficiency (PID)
- Lead sponsor
- Biopharma Plasma LLC
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 17, 2025
- Completion date
- July 1, 2028
- Enrollment
- 56 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.